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Abstract
Clonal hematopoiesis (CH) is a common aging-associated condition with increased risk of hematologic malignancy.
Knowledge of the mechanisms driving evolution from CH to overt malignancy has been hampered by a lack of in vivo
models that orthogonally activate mutant alleles. Here, we develop independently regulatable mutations in DNA
methyltransferase 3A (Dnmt3a) and nucleophosmin 1 (Npm1), observed in human CH and AML, respectively. We ﬁnd
Dnmt3a mutation expands hematopoietic stem and multipotent progenitor cells (HSC/MPPs), modeling CH. Induction of
mutant Npm1 after development of Dnmt3a-mutant CH causes progression to myeloproliferative disorder (MPD), and more
aggressive MPD is observed with longer latency between mutations. MPDs uniformly progress to acute myeloid leukemia
(AML) following transplant, accompanied by a decrease in HSC/MPPs and an increase in myeloid-restricted progenitors, the
latter of which propagate AML in tertiary recipient mice. At a molecular level, progression of CH to MPD is accompanied
by selection for mutations activating Ras/Raf/MAPK signaling. Progression to AML is characterized by additional
oncogenic signaling mutations (Ptpn11, Pik3r1, Flt3) and/or mutations in epigenetic regulators (Hdac1, Idh1, Arid1a).
Together, our study demonstrates that Npm1 mutation drives evolution of Dnmt3a-mutant CH to AML and rate of disease
progression is accelerated with longer latency of CH.
Introduction
Clonal hematopoiesis (CH) occurs when stem and pro-
genitor cell clones gain one or more somatic mutations that
confer a competitive advantage [1]. This can be observed in
patients by an increase in the variant allele frequency (VAF)
of somatic mutations in the blood or bone marrow (BM) [2].
There is a vast spectrum of outcomes in individuals with
CH; in many cases, CH causes little to no clinically relevant
hematopoietic phenotype. At the other extreme, CH cases
represent a permissive state for development of BM failure
syndromes including myelodysplastic syndrome (MDS)
[3, 4], myeloproliferation including myeloproliferative dis-
order (MPD) [5], or leukemias including acute myeloid
leukemia (AML), the last of which is accompanied by
additional somatic mutations [6–8]. Pressing clinical issues
include how to identify individuals with CH for which this
condition should be considered a medically important event
and how to develop therapies that might prevent onset of
hematologic malignancies. To answer these questions, we
need to understand the factors (speciﬁc somatic mutations,
genetic background of the individual, environmental fac-
tors, etc.) that cause evolution of CH to hematologic
malignancies. A current barrier is the lack of available
animal models that undergo the evolution of CH to hema-
tologic malignancies in a native in vivo environment.
The most common somatic mutations present in CH are
in genes associated with epigenetic modiﬁcations, including
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the DNA methyltransferase DNMT3A, and splicing factors.
Several mouse models of DNMT3A-driven CH have been
generated by conditional knockout [9], mutant allele
knockin [10, 11], or mutant allele overexpression [12].
Further, several studies have identiﬁed cooperating muta-
tions that can act synergistically with Dnmt3a knockout or
mutation to cause leukemia, such as Flt3ITD [13, 14], Flt3ITD
and Npm1c [11], cKit [15], and KrasG12D [16]. However,
existing combinatorial mutation models are limited by the
use of germline alleles with conditional alleles (thereby not
modeling the known somatic nature of these mutations),
multiple conditional alleles that are induced simultaneously
by Cre recombination, or conditional alleles combined with
ex vivo transduction/overexpression of cooperating muta-
tions. Thus, based on the design of previous mouse models,
none are able to evaluate the evolution of CH to hemato-
logic malignancies within a native in vivo environment.
To overcome these limitations, we have developed an
inducible, dual-recombinase system combining ﬂippase-
FRT (Flp-FRT) and Cre-loxP recombination technologies
[17, 18] to improve genetically engineered mouse models of
CH and to allow study of the evolution of CH to hemato-
poietic malignancy. This dual-recombinase system allows
for sequential induction of a Dnmt3a hotspot mutation in
R878H (Dnmt3aR878H), replicating human R882H [1], and
the recurrent hotspot mutation in the multifunctional nuclear
protein Npm1 (Npm1c type A; Npm1cA) [19, 20]. Pre-
viously, concurrent expression of Dnmt3aR878H and Npm1cA
mutations was not found to cause a lethal malignancy
within a 45-week observation period [11]; however, it
remains unknown whether malignancy would have occur-
red over a longer timeframe or with a latency period
between expression of these two mutations. Therefore, we
have utilized our model to examine the cellular and mole-
cular alterations during evolution of CH to hematologic
malignancy within a native in vivo environment.
Materials and methods
Genetic engineering of Dnmt3aﬂ-R878H/+ and Npm1frt-cA/+
mice
Targeting vectors mDnmt3a_LSL_exon23_bGHpA_pBlight
and mNpm1_FS12_exon11_FSF_pBlight were generated by
in vitro synthesis (GenScript). The Dnmt3aﬂ-R878H/+ con-
struct design placed wild-type exon 23 in a loxP-ﬂanked
STOP cassette (4xSV40pA) into the intron between exons
22 and 23, and the 3′ homology arm included the 2633 G>A
in exon 23 to encode the R878H mutation. The Npm1frt-cA/+
construct design placed wild-type exon 11 in an FRT-
ﬂanked STOP cassette (4xSV40pA) into the intron between
exons 10 and 11, and the 3’ homology arm included a
frameshift mutation to create a humanized mutant exon 11
(p.W288fs*12). Constructs were linearized and electro-
porated into C57BL/6 embryonic stem (ES) cells. Clones
were screened by loss-of-allele PCR, conﬁrmed by Southern
blot and microinjected into C57BL/6 blastocysts. PCR
genotyping of pups was used to screen for germline trans-
mission (primer sequences in Table S1).
Experimental animals
C57BL/6J and B6.SJL-PtprcaPepcb/BoyJ (referred to as “B6.
CD45.1”) mice were obtained from, and aged within, The
Jackson Laboratory. Dnmt3aﬂ-R878H/+ mice were crossed to
B6.Cg-Tg(Mx1-cre)1Cgn/J mice (referred to as Mx1-Cre)
[21]. Npm1frt-cA/+ mice were crossed to B6N.129S6(Cg)-Gt
(ROSA)26Sortm3(CAG-ﬂpo/ERT2)Alj/J (referred to as R26FlpoER)
[22]. Unless otherwise noted, all mice were female and
experiments initiated at 8–16 weeks of age. Mice were
injected ﬁve times (once every other day) via intraperitoneal
(IP) injection with 15mg/kg high molecular weight
polyinosinic-polycytidylic acid (pIpC) (InvivoGen) to induce
Mx1-Cre recombinase expression. Mice were administered
125mg/kg tamoxifen three times (on consecutive days) via
oral gavage to induce R26FlpoER recombinase expression.
Before and after pIpC or tamoxifen administration, genomic
DNA was extracted from PB cells for recombination PCR
using primers speciﬁed above (Table S1). In addition, RNA
was extracted and cDNA synthesized from whole BM cells
for Sanger sequencing to verify mutant allele expression.
Real-time PCR was utilized to examine relative expression of
Dnmt3a in Dnmt3aﬂ-R878H/+ Mx1-cre+ animals prior to pIpC
injection (primer sequences in Table S1). To verify cellular
localization of Npm1cA, spleens from Npm1cA/+ R26FlpoER or
control Npm1+/+ R26FlpoER mice were ﬁxed, parafﬁn
embedded, and sectioned for immunohistochemistry using a
polyclonal antibody raised against human NPM1 (Cell Sig-
naling Technology). The Jackson Laboratory’s Institutional
Animal Care and Use Committee (IACUC) approved all
experiments.
Primary cell isolation and hematopoietic stem/
progenitor cell phenotyping
Single-cell suspensions of BM were prepared by ﬁltering
crushed, pooled femurs, tibiae, and iliac crests from each
mouse. BM mononuclear cells (MNCs) were isolated by
Ficoll-Paque (GE Healthcare Life Sciences) density cen-
trifugation and stained with a combination of ﬂuorochrome-
conjugated antibodies from eBioscience, BD Biosciences, or
BioLegend: CD45.2 (clone 104), c-Kit (clone 2B8), Sca-1
(clone 108129), CD150 (clone TC15-12F12.2), CD48 (clone
HM48-1), FLT3 (Clone A2F10), CD34 (clone RAM34),
FcγR (clone 2.4G2), mature lineage (Lin) marker mix (B220
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(clone RA3-6B2), CD11b (clone M1/70), CD4 (clone RM4-
5), CD8a (clone 53-6.7), Ter-119 (clone TER-119), Gr-1
(clone RB6-8C5)), and the viability stain propidium iodide
(PI). Stained cells were either analyzed or sorted using a
FACSAria with Diva software (BD Biosciences) based on the
following surface marker proﬁles: LSK (Lin− Sca-1+ c-Kit+),
LT-HSC (Lin− Sca-1+ c-Kit+ Flt3− CD150+ CD48−), ST-
HSC (Lin− Sca-1+ c-Kit+ Flt3− CD150− CD48−), MPP2
(Lin− Sca-1+ c-Kit+ Flt3− CD150+ CD48+), MPP3 (Lin−
Sca-1+ c-Kit+ Flt3− CD150− CD48+), MPP4 (Lin− Sca-1+
c-Kit+ Flt3+), myeloid-restricted progenitors (MyPro; Lin−
Sca-1− c-Kit+), GMP (Lin− Sca-1- c-Kit+ CD150− CD34+
FcγR+), CMP (Lin− Sca-1− c-Kit+ CD150− CD34+ FcγRlo)
and MEP (Lin− Sca-1− c-Kit+ CD150− CD34− FcγR−). All
ﬂow cytometry data was analyzed using FlowJo software.
Colony formation unit (CFU) assay
De novo isolated cells were plated in MethoCult GF M3434
(StemCell Technologies) at the indicated numbers and
cultured at 37 °C and 5% CO2. Colonies were scored
between 6 and 14 days post-plating using a Nikon Eclipse
TS100 inverted microscope. For CFU replating assay,
colonies were harvested, total viable cell counts obtained,
and then 5 × 104 cells were replated in MethoCult GF
M3434. To examine allele recombination at the clonal level,
whole BM was plated from Dnmt3aR878H/+ Npm1cA/+ mice
with MDS/MPD or MPD phenotypes. Individual colonies
were picked under a Nikon Eclipse microscope (4× mag-
niﬁcation) and used for colony PCR to examine recombi-
nation of Dnmt3aR878H and Npm1cA alleles (primers listed in
Table S1).
In vivo transplantation
For competitive transplantation, 2 × 106 BM MNCs from
Dnmt3aﬂ-R878H/+ Mx1-Cre or Dnmt3a+/+ Mx1-Cre mice
were combined at a 1:1 ratio with 2 × 106 BM MNCs from
B6.CD45.1 mice and intravenously injected into female
recipient B6.CD45.1 mice that received a lethal dose of
gamma irradiation (1200 rads, split dose). Recipient mice
received pIpC injections as described at 5 weeks post-
transplant. For non-competitive transplantation, 106 BM
MNCs from Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre R26FlpoER
or Dnmt3a+/+ Npm1+/+ Mx1-Cre R26FlpoER mice were
intravenously injected into female recipient B6.CD45.1
mice that received a lethal dose of gamma irradiation (1200
rads, split dose). Recipient mice received pIpC injections as
described at 4–5 weeks post-transplant, and tamoxifen
administration at various times post-pIpC as indicated.
Recipient mice were monitored every 4 weeks thereafter by
ﬂow cytometry analysis of PB samples using a cocktail of
CD45.1 (clone A20), CD45.2, CD11b, B220, CD3ε (clone
145-2C11), and Gr-1 on an LSRII (BD). For secondary
transplantation studies, female B6.CD45.1 mice received a
sublethal dose of gamma irradiation (600 rads) and were
intravenously injected with 106 BM MNCs from moribund
primary recipients of Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre
R26FlpoER cells. For tertiary transplantation studies, female
B6.CD45.1 mice received a sublethal dose of gamma irra-
diation (600 rads) and were intravenously injected with 5 ×
103 sorted MyPro (Lin− Sca-1− c-Kit+) from moribund
secondary recipients of Dnmt3aR878H/+ Npm1cA/+ Mx1-Cre
R26FlpoER cells.
Analysis of moribund mice
Mice demonstrating declining health status were sacriﬁced
and PB, spleen, liver, and BM harvested. Differential blood
cell counts were obtained from PB using an Advia 120
Hematology Analyzer (Siemens). Single-cell suspensions of
PB, spleen, and BM were analyzed by ﬂow cytometry for
mature lineage markers and c-Kit on an LSRII. Cytospin
preparations of whole BM MNCs were stained with May–
Grunwald–Giemsa stain. Liver and spleens were ﬁxed for
24 h in 10% buffered formalin phosphate, embedded in
parafﬁn, and sections were stained with H&E. Images of
stained BM, liver, and spleen slides were captured on a
Nikon Eclipse E200 upright microscope with SPOT ima-
ging software (v.5.2).
M-IMPACT
Genomic DNA was extracted from isolated BM cells of
diseased mice and WT littermates. DNA underwent targeted
capture and deep sequencing performed by the MSKCC
Integrated Genomics Operation Core using the MSK mouse
Integrated Mutation Proﬁling of Actionable Cancer Targets
(M-IMPACT) v1 assay. M-IMPACT is a DNA sequencing
assay, which captures and sequences the exons and select
introns of 578 known cancer genes, using solution-phase
hybridization-based exon capture as described previously
[23]. Gene selection, mouse ortholog mapping, and bait
design has been described previously [23, 24]. Mouse geno-
mic DNA (250 ng) was used for library construction with
molecular barcoding of each sample occurring prior to capture
and sequencing. Equimolarly pooled libraries containing
captured DNA fragments were subsequently sequenced on
one lane of an Illumina HiSeq system for paired end 125/125
reads with intended 500× coverage for all reads. Sequencing
analysis was performed by the MSKCC Bioinformatics Core.
Processed FASTQ ﬁles were mapped to the mouse reference
genome mm10 (GRCm38) using BWA-MEM (Burrows-
Wheeler Aligner v0.7.12; http://arxiv.org/abs/1303.3997).
Resulting ﬁles were sorted, grouped, and PCR duplicates
identiﬁed by MarkDuplicates in PICARD Tools (v1.124;
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https://github.com/broadinstitute/picard). BAM ﬁles were
processed through GATK toolkit (v3.2) [25] to perform var-
iant calling in tumor-vs-normal paired mode. Speciﬁcally,
somatic single-nucleotide variants (SNVs) were called from
processed BAM ﬁles using muTect (v1.1.7) [26]. Haplotype
caller from GATK was used to identify somatic small inser-
tions and deletions (indels) with a custom post-processing
script (https://github.com/soccin/Variant-PostProcess). Var-
iant allele frequency (VAF) was determined by calculating the
fraction of variant reads for a speciﬁc out of the total reads at
that location.
Statistical analysis
No sample group randomization or blinding was performed.
For overall survival, Log-rank (Mantel–Cox) test was
performed on Kaplan–Meier survival curves. Statistical
analysis of non-survival data was performed by unpaired
student’s t-test, non-parametric one-way ANOVA
(Kruskal–Wallis test) followed by Dunn’s multiple com-
parisons test, or two-way ANOVA followed by Tukey’s
multiple comparisons test. For these experiments, a mini-
mum of three samples per condition was chosen to detect
statistical differences with >80% power at an error rate of
5%. All statistical tests, including evaluation of normal
distribution of data and examination of variance between
groups being statistically compared, were assessed using
Prism 7 software (GraphPad).
Results
Generation of an independently regulatable
Dnmt3aR878H allele
To generate an inducible mouse model of human DNMT3A-
mutant (DNMT3AR882H) CH, we engineered a Cre-inducible
knockin model of the equivalent Dnmt3aR878H mutation in
mice (Fig. 1a, Fig. S1A,B). While the general targeting
strategy was similar to two recently published knockin
models of Dnmt3aR878H [10, 11], our model has unique
advantages of preserving expression of wild-type Dnmt3a
prior to Mx1-Cre-mediated recombination (Fig. S1C) and
following recombination, the Dnmt3aR878H mutant allele
retains endogenous polyA and 3′ UTR elements. Indeed,
prior to induction of Mx1-Cre by injection of poly(I:C)
(pIpC), there is no observable change in frequency of the
hematopoietic stem and progenitor cell compartment in the
BM of Dnmt3aﬂ-R878H mice (Fig. S1D). Furthermore, there
is no observable change in frequency of stem and progenitor
cell subsets including long-term HSCs (LT-HSC), short-
term HSCs (ST-HSC), multipotent progenitor cell 2
(MPP2), MPP3, and MPP4 in the BM of Dnmt3aﬂ-R878H
mice (Fig. S1E, gating strategy shown in Fig. S1F). Thus,
our mice model somatic acquisition of Dnmt3a mutation as
it is observed in human CH.
Dnmt3aR878H/+ expands the HSC and MPP
compartments
As Dnmt3a mutation is considered to be an early event
causing CH, we ﬁrst investigated the phenotype of our
Dnmt3aR878H/+ Mx1-Cre mice. At 6 months following acti-
vation of Cre recombinase expression, we observed a sig-
niﬁcant expansion of both the percentage and total number
of viable LT-HSC, ST-HSC, MPP3, and myeloid progeni-
tors (MyPro) in Dnmt3aR878H/+ vs. control Dnmt3a+/+ mice
(Fig. 1b, c). To examine the clonogenic potential of
Dnmt3aR878H/+ cells, we isolated whole BM cells from
control and Dnmt3aR878H/+ mice for colony-forming unit
(CFU) assays. We observed similar numbers of total CFU
emerging from control and Dnmt3aR878H/+ mice (Fig. 1d).
However, there was a signiﬁcant expansion of multi-lineage,
mixed granulocyte/erythroid/macrophage/megakaryocyte
(GEMM) colonies (Fig. 1e), consistent with an expansion of
multipotent stem and progenitor cells in the BM. Together,
this data is generally consistent with human data demon-
strating that the HSC compartment is most dramatically
altered by the Dnmt3aR882H somatic mutation [8] and
existing mouse Dnmt3aR878H models demonstrating expan-
sion of stem and progenitor cells [10, 11].
To test the competitive ﬁtness of Dnmt3aR878H/+ LT-
HSCs, we examined their ability to competitively recon-
stitute the hematopoietic system of an irradiated host. We
isolated BM cells from control and Dnmt3aR878H/+ mice that
had not yet received pIpC and transplanted them at a 1:1
ratio with wild-type B6.CD45.1 BM cells into lethally irra-
diated congenic B6.CD45.1 recipient mice (Fig. 1f). At
5 weeks post-transplant, following initial homing and
engraftment of transplanted LT-HSCs, all recipients were
administered pIpC to induce Mx1-Cre expression and fol-
lowed by monthly peripheral blood (PB) ﬂow cytometry
analysis. We observed that the chimerism (% CD45.2+ cells)
in the PB was signiﬁcantly higher from Dnmt3aR878H/+ cells
compared to control Dnmt3a+/+ cells (Fig. 1g), supporting a
competitive advantage of Dnmt3aR878H/+ HSCs. To deter-
mine whether this chimerism was biased toward production
of particular types of mature hematopoietic cells, we
examined myeloid (CD11b+), B cell (B220+) and T cell
(CD3+) populations, and Gr-1+ and Gr-1− cells (within the
myeloid fraction) of donor-derived CD45.2+ PB cells. We
observed no differences in mature hematopoietic lineage
composition between Dnmt3aR878H/+ and control Dnmt3a+/+
cells (Fig. 1h, i). In contrast, examination of chimerism
within the hematopoietic stem and progenitor cell compart-
ment of recipient mice revealed increased numbers of donor-
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derived LT-HSC, ST-HSC, MPP3, and myeloid-restricted
progenitors (MyPro) (Fig. 1j). As this result closely resem-
bles the hematopoietic stem and progenitor cell expansion in
non-transplanted mice (Fig. 1c), these data together indicate
that this expansion is a cell-intrinsic effect of the
Dnmt3aR878H/+mutation.
Generation of an independently regulatable Npm1cA
allele
To develop an independently regulatable cooperating
mutation that may synergize with Dnmt3aR878H to drive
AML, we generated a Flp-inducible knockin mouse model
Fig. 1 Dnmt3aR878H/+ expands HSCs and multipotent progenitor cells.
a Schematic diagram of the design of the Dnmt3aﬂ-R878H/+ allele.
Asterisk indicates 2633G>A in exon 23 to encode the R878H muta-
tion. b Frequency and c total number of LT-HSC, ST-HSC, MPP2,
MPP3, MPP4, and MyPro cells in the BM of+/+ (n= 4) and R878H/+
(n= 6) mice at 6 months post-pIpC. d Total colony-forming units
(CFU) and e colony types derived from 50 K BMMNCs isolated from
+/+ (n= 6) and R878H/+ (n= 8) mice at 4 months post-pIpC. G
(granulocyte), M (macrophage), GM (granulocyte-macrophage),
BFUE (burst forming-unit erythroid), GEMM (mixed granulocyte-
erythroid-macrophage-megakaryocyte). Results are from three inde-
pendent experiments. f Experimental design for competitive trans-
plantation of+/+ or ﬂ-R878H/+ BM cells with wild-type B6.CD45.1
BM cells at a 1:1 ratio into lethally irradiated B6.CD45.1 recipient
mice followed by pIpC to induce recombination of Dnmt3aﬂ-R878H.
g Frequency of donor-derived (CD45.2+)+/+ (n= 9) or R878H/+
(n= 9) cells in PB of recipient mice post-pIpC. Results are from
two independent experiments. h Frequency of myeloid (CD11b+),
B (B220+), and T (CD3+) cells within donor-derived (CD45.2+) PB
and i Gr-1+ and Gr-1− cells within donor-derived myeloid PB at
6 months post-pIpC. j Frequency of LT-HSC, ST-HSC, MPP2, MPP3,
and MyPro cells within donor-derived+/+ (n= 5) or R878H/+
(n= 5) BM at 6 months post-pIpC. Results are from two independent
experiments. In all graphs, dots represent individual mice, bars indicate
mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001
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of humanized Npm1cA (Fig. 2a, Fig. S2A–C). Mutations
involving the NPM1 are found in one-third of all AML
cases [20]. NPM1 mutations (referred to as NPM1c) disrupt
tryptophan residues and generate an additional nuclear
export signal leading to aberrant localization of NPM1c in
the cytoplasm [27]. Our general targeting strategy was
similar to a published knockin model of humanized
Npm1ﬂox-cA [28]; however, our model has a unique advan-
tage of being Flp recombinase-inducible by the use of FRT
sites rather than loxP sites. This strategy allows for inde-
pendent regulation of the Dnmt3a and Npm1 mutant alleles.
We utilized a Rosa26-knockin tamoxifen-inducible FlpoER
mouse strain [22] to induce expression of Npm1cA following
administration of tamoxifen. To compare alterations in the
hematopoietic stem and progenitor cell compartment driven
by Npm1cA as a single mutation with the Dnmt3aR878H/+
phenotype, we examined the frequency and total number of
stem and progenitor cells in Npm1cA/+ mice at 4 months
post-tamoxifen injection. This revealed a signiﬁcant
decrease in frequency of LT-HSC (Fig. 2b) as well as total
numbers of LT-HSC and ST-HSC (Fig. 2c) in Npm1cA/+
compared to Npm1+/+ control mice. To examine the clo-
nogenic potential of Npm1cA/+ cells, we isolated whole BM
cells from control and Npm1cA/+ mice at 4 months post-
tamoxifen injection for CFU assays. We observed a sig-
niﬁcant increase in the total number of colonies formed
(Fig. 2d) and expansion in both granulocyte (G) and
granulocyte-macrophage (GM) colony types (Fig. 2e). This
Npm1cA/+ in vitro phenotype is in contrast to the
Dnmt3aR878H/+ BM, which demonstrated an expansion of
the multi-lineage GEMM colony type (Fig. 1e). Lastly, as
Npm1cA/+ has been demonstrated to cause myeloprolifera-
tion and AML with 30% penetrance late in life (median
survival 617 days) [28], we examined mature hematopoietic
cell lineage composition in the PB in our Npm1cA/+ mice at
4 months post-tamoxifen injection. We observed no
alteration in frequency of mature hematopoietic lineages in
Npm1cA/+ mice compared to controls (Fig. 2f, g), suggest-
ing that at the time point at which we observe changes in the
hematopoietic stem and progenitor cell compartment and
clonogenicity of BM cells, there is no overt peripheral
myeloproliferation.
Dnmt3aR878H/+ Npm1cA/+ mice develop a lethal
myeloproliferative disorder
We then crossed the Npm1frt-cA/+ mice with the Dnmt3aﬂ-
R878H/+ Mx1-Cre model, to generate compound Dnmt3aﬂ-
R878H/+ Npm1frt-cA/+ Mx1-Cre R26FlpoER mice. We induced
expression of the Dnmt3aR878H mutation ﬁrst then followed
this with induction of Npm1cA expression three months later
to allow development of CH in the interim period (Fig. 3a).
We ﬁrst examined the clonogenic potential of BM cells
isolated from these Dnmt3aR878H/+ Npm1cA/+ mice. We
observed a signiﬁcant increase in total CFU from
Dnmt3aR878H/+ Npm1cA/+ BM compared to control
(Fig. 3b). Assessing colony morphology revealed a sig-
niﬁcant increase in granulocyte (G) and granulocyte-
macrophage (GM) colony types (Fig. 3c). Serial replating
of Dnmt3aR878H/+ Npm1cA/+ colonies revealed robust pro-
liferative and clonogenic potential for at least 13 passages
(Fig. 3d), suggesting unlimited in vitro self-renewal
potential.
To determine whether this enhanced clonogenic potential
was reﬂective of transformation, we transplanted BM from
control Dnmt3a+/+ Npm1+/+, single mutant Npm1frt-cA/+ or
double mutant Dnmt3aﬂ-R878H/+ Npm1frt-cA/+ mice into
lethally irradiated recipient mice, administered pIpC at 1-
month post-transplant, tamoxifen at 3 months post-pIpC,
and followed the natural life course of the recipients
(Fig. 3e). Importantly, this experimental design restricted
expression of Dnmt3aR878H and Npm1cA exclusively to the
hematopoietic compartment. We observed that within a
440-day period, 100% of Dnmt3aR878H/+ Npm1cA/+ reci-
pient mice died while only 29% of single mutant Npm1cA/+
recipient mice died (Fig. 3f). The phenotypes at the time of
death comprised two major groups; 67% (6 out of 9)
Dnmt3aR878H/+ Npm1cA/+ mice had mixed myelodysplastic
syndrome and myeloproliferative disorder (MDS/MPD)
while 33% (3 out of 9) Dnmt3aR878H/+ Npm1cA/+ mice and
29% (2 out of 7) single mutant Npm1cA/+ mice had MPD
(Fig. 3g). The single mutant Npm1cA/+ mice developed
MPD with survival times of ~7.5–8 months post-tamoxifen,
demonstrating that this mutation is capable of causing
myeloproliferation beyond our original 4-month post-
tamoxifen sampling (Fig. 2f).
An extensive characterization of Dnmt3aR878H/+ Npm1cA/+
MDS/MPD, Dnmt3aR878H/+ Npm1cA/+ MPD and single
mutant Npm1cA/+MPD was performed to contrast phenotypic
similarities and differences. The Dnmt3aR878H/+ Npm1cA/+
MDS/MPD phenotype was characterized by erythroid and
myeloid dysplasia (Fig. 3h), pancytopenia including sig-
niﬁcantly decreased white blood cell (WBC) (Fig. 3i), red
blood cell (RBC) (Fig. 3j), and platelet (PLT) counts
(Fig. 3k), increased PB myeloid cell production (Fig. S3A),
and myeloid cell inﬁltration into the spleen and liver
(Fig. S3C,E). The Dnmt3aR878H/+ Npm1cA/+ MPD phenotype
was characterized by signiﬁcantly increased WBC count
(Fig. 3i), signiﬁcantly decreased RBC and PLT counts
(Fig. 3j, k), signiﬁcantly increased spleen weight (Fig. S3D),
increased PB myeloid cell production with monocyte bias
(Fig. S3A,B), and myeloid (monocyte) cell inﬁltration into the
spleen and liver (Fig. S3C–F). The single mutant Npm1cA/+
MPD phenotype was distinguished from Dnmt3aR878H/+
Npm1cA/+ MPD phenotype by lower WBC count (Fig. 3i),
lower spleen weight (Fig. S3D) and greater monocyte bias in
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myeloid PB cells (Fig. S3B). Together, these data demon-
strate that acquiring the Npm1cA mutation on pre-existing
Dnmt3aR878H/+ CH causes progression to MDS/MPD or
MPD.
To demonstrate one application of independently reg-
ulatable disease alleles, we examined whether the duration
of pre-existing Dnmt3aR878H/+ CH would impact disease
development or survival of mice. Npm1cA/+ was induced at
3, 10, 32, or 57 weeks post-recombination of Dnmt3aR878H/+
(Fig. 3l). We observed that longer latency between
acquisition of Dnmt3a and Npm1 mutations resulted in a
signiﬁcantly shorter survival time post-tamoxifen (3 vs.
10 weeks, P= 0.067; 3 vs. 32 weeks, ***P= 0.0009; 3 vs.
57 weeks, ***P < 0.0001) (Fig. 3m). This suggests that a
greater length of time with Dnmt3a-mutant clonal expan-
sion increases the risk of progression to malignancy.
Dnmt3aR878H/+ Npm1cA/+ MPD progresses to AML
upon transplant
While human NPM1 mutations are most often observed in
de novo AML, several studies have shown that NPM1
mutations can be present in MDS or MDS/myeloprolifera-
tive neoplasm (MPN) prior to blast counts reaching the
threshold for AML diagnosis [29, 30]. This suggests
Dnmt3aR878H/+ Npm1cA/+ MDS/MPD or MPD might have
potential for further progression to AML. To determine
whether Dnmt3aR878H/+ Npm1cA/+ MPDs were transplan-
table to recipient mice and to test whether they are capable
of further progression to AML, we isolated BM cells from
primary Dnmt3aR878H/+ Npm1cA/+ transplant recipients with
either the MDS/MPD or MPD phenotypes and transplanted
these cells into sublethally irradiated secondary recipient
Fig. 2 Npm1cA/+ depletes HSCs and expands myeloid colony-forming
cells. a Schematic diagram of the design of the Npm1frt-cA/+ allele.
Asterisk indicates frameshift mutation to create a humanized mutant
exon 12 (p.W288fs*12). b Frequency and c total number of LT-HSC,
ST-HSC, MPP2, MPP3, MPP4, and MyPro cells in the BM of+/+
(n= 5) and cA/+ (n= 5) mice at 4 months post-tamoxifen. d Total
CFU and e colony types derived from 50K BM MNCs isolated
from+/+ (n= 8) and cA/+ (n= 8) mice at 4 months post-tamoxifen.
Results are from four independent experiments. f Frequency of mye-
loid, B, and T cells within PB and g Gr-1+ and Gr-1− cells within
myeloid PB at 4 months post-tamoxifen in+/+ (n= 6) and cA/+
(n= 12) mice. In all graphs, dots represent individual mice, bars
indicate mean ± s.e.m. *P < 0.05; ***P < 0.001
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mice (Fig. 4a). We assessed donor cell engraftment
(% CD45.2+) at 4 weeks post-transplant as well as when
these mice were moribund. This analysis revealed that MPD
samples achieved high levels of engraftment in secondary
recipients almost immediately post-transplant (Fig. 4b). In
contrast, MDS/MPD samples had initially low levels of
engraftment in secondary recipients but dramatically
expanded to achieve high levels of engraftment at the time
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of sacriﬁce. There was a signiﬁcant difference between the
survival of mice transplanted with MDS/MPD donors
(median survival 188 days) vs. MPD donors (median sur-
vival 36 days) (Fig. 4c). However, these both represent a
dramatic disease acceleration compared to the primary
recipient animals (Fig. 3f).
We observed that 100% of secondary transplant recipient
mice succumbed to acute myeloid leukemia (AML),
regardless of whether they were derived from an MDS/
MPD or MPD primary donor. All Dnmt3aR878H/+ Npm1cA/+
recipients showed signiﬁcantly increased WBC count and
decreased RBC and PLT counts (Fig. 4d), increased spleen
weight (Fig. 4e), complete myeloid cell dominance in the
PB with monocyte bias (Fig. 4f, g), >20% blast cells in the
BM and vast inﬁltration of blast cells in the spleen and liver
(Fig. 4h). Together these data suggest that Dnmt3aR878H/+
Npm1cA/+MDS/MPD and MPD can both progress to AML.
To examine clonality of recombination of Dnmt3aﬂ-R878H
and Npm1frt-cA alleles in mice with MDS/MPD, MPD and
AML, we performed a BM CFU assay and picked indivi-
dual colonies for PCR. We observed that in MDS/MPD,
82% of colonies had recombination of both Dnmt3aR878H
and Npm1cA (Fig. S3G). In MPD and AML, 100% of
colonies had recombination of both Dnmt3aR878H and
Npm1cA. This demonstrates similar levels of recombination
in Dnmt3aR878H/+ Npm1cA/+ MDS/MPD, MPD, and AML.
To further examine additional acquired somatic mutations,
we performed somatic mutational analysis of BM from
MDS/MPD, MPD and AML samples using a custom
targeted sequencing panel querying 578 known cancer
genes (MSK-Mouse IMPACT; M-IMPACT) (Table S2).
We observed that Dnmt3aR878H/+ Npm1cA/+MDS/MPD was
associated with mutations in the tumor suppressor Cux1,
previously shown to drive MDS and MDS/MPD [31] and in
the RNA splicing genes Rbm10 and U2af2 (Fig. 4i,
Table S3). Mutations in key factors of the spliceosome are
known to occur frequently in CH and MDS [32]. Devel-
opment of Dnmt3aR878H/+ Npm1cA/+ MPD was associated
with mutations activating the Ras/Raf/MAPK pathway
(including Nf1, Nras, Kras, and Braf) at high VAF, con-
sistent with known function of these mutations [33, 34].
Progression to Dnmt3aR878H/+ Npm1cA/+ AML was also
associated with these same mutations, but with the addition
of mutations activating the tyrosine phosphatase SHP2
(Ptpn11), PI3K (Pik3r1), or Flt3 (Flt3) signaling as well as
mutations involved in epigenetic regulation including Brd4,
Hdac1, Idh1, and Arid1a. Many of these genes are recur-
rently mutated in human AML [35–37], and demonstrate
additional mutations are required to cooperate with mutant
Dnmt3a and Npm1 to promote transformation to MDS/
MPD, MPD and AML.
Dnmt3aR878H/+ Npm1cA/+ AML mice have decreased
HSC and increased myeloid progenitors
To determine how Dnmt3aR878H/+ CH progresses to MPD
and AML with acquisition of Npm1cA mutation, we
examined the BM stem and progenitor cell compartment
of primary and secondary recipient mice transplanted with
Dnmt3aR878H/+ Npm1cA/+ cells (representative gating
shown in Fig. 5a). We observed a signiﬁcant increase in
LTHSC frequency in the Dnmt3aR878H/+ Npm1cA/+ MDS/
MPD group and decrease in LT-HSC frequency in the
Dnmt3aR878H/+ Npm1cA/+ AML group compared to con-
trol transplanted mice (Fig. 5b). In addition, we observed
a signiﬁcant decrease in ST-HSC frequency in the
Dnmt3aR878H/+ Npm1cA/+ MPD and AML groups com-
pared to control transplanted mice. Strikingly, we
observed that granulocyte-macrophage progenitors
(GMP) were signiﬁcantly expanded in the Dnmt3aR878H/+
Npm1cA/+ MPD and AML groups vs. the control group
(Fig. 5c). Together, these data suggest that Npm1cA
transformation of Dnmt3aR878H/+ CH is accompanied by a
shift in the stem and progenitor cell compartment towards
expansion of myeloid-restricted progenitor cells at the
expense of HSCs.
Dnmt3aR878H/+ Npm1cA/+ AML is propagated by
myeloid-restricted progenitors
Within Dnmt3aR878H/+ Npm1cA/+ AML, the shift in the stem
and progenitor cell compartment towards expansion of
Fig. 3 Dnmt3aR878H/+ followed by Npm1cA/+ causes development of
lethal MPD. a Experimental design for induction of Dnmt3aR878H/+
driving clonal hematopoietic expansion prior to induction of Npm1cA/+,
followed by in vitro CFU assay. b Total CFU and c colony types derived
from 50K BM MNCs isolated from control (n= 4) or R878H/+ cA/+
(n= 8) mice at 3 months post-tamoxifen. Results are from 3
independent experiments. (d) CFU derived from 50K BM MNCs
isolated from control (n= 2) and R878H/+ cA/+ (n= 4) mice, serially
passaged for up to 13 passages. Results are from two independent
experiments. e Experimental design for non-competitive transplanta-
tion of ﬂ-R878H/+ frt-cA/+ BM into lethally irradiated recipient
mice, followed by pIpC induction of R878H/+ and clonal hemato-
poietic expansion prior to tamoxifen induction of cA/+. f Overall
survival of mice transplanted with 106 BM cells from control (n= 3),
cA/+ only (n= 7) or R878H/+ cA/+ (n= 13) mice. Results are from
three independent experiments. g Description and penetrance of phe-
notypes in moribund mice following transplant with cA/+ only or
R878H/+ cA/+ BM cells. h Representative Giemsa-stained BM
cytospins (100×) from R878H/+ cA/+MDS/MPD showing dysplastic
cells (arrows). Scale bars are 10 μm. i WBC count, j RBC count, and
k PLT count in moribund mice (control, n= 3; cA/+MPD, n= 2;
R878H/+ cA/+ MDS/MPD, n= 6; R878H/+ cA/+ MPD, n= 3).
l Experimental design for tamoxifen induction of cA/+ at various
times following induction of R878H/+. m Overall survival of mice
transplanted with 106 BM cells with latency between R878H/+ and
cA/+mutations of 3 weeks (n= 10), 10 weeks (n= 11), 32 weeks
(n= 3), or 57 weeks (n= 5). Results are from three independent
experiments. In all graphs, dots represent individual mice, bars indicate
mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001
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myeloid-restricted progenitor cells suggests that these cells
may represent tumor-propagating cells capable of
transferring disease to recipient mice. To test this, we per-
formed a tertiary transplant of sorted myeloid progenitors
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(Lin− c-Kit+ Sca-1−) (Fig. 6a). We observed that 100% of
tertiary transplant recipient mice succumbed to acute mye-
loid leukemia (AML) with a median survival of 56 days
(Fig. 6b), similar to the rate and penetrance of AML
development in secondary transplant recipients (Fig. 4c).
This is evidenced in all recipients by signiﬁcantly increased
WBC and decreased PLT (Fig. 6c) counts, increased spleen
weight (Fig. 6d), >20% blast cells in the BM and vast
inﬁltration of blast cells in the spleen and liver (Fig. 6e).
Together, these data support diagnosis of AML in second-
ary recipient animals and demonstrate that myeloid-
restricted progenitors are leukemia stem cells (LSCs) cap-
able of propagating Dnmt3aR878H/+ Npm1cA/+ AML.
Discussion
Individuals with CH have an increased risk of development
of hematologic malignancy, including AML. Currently, no
methods exist to distinguish individuals with benign CH
from those with pre-malignant CH due to a lack of under-
standing of the mechanisms by which CH progresses to
AML. Improved in vivo models of the progression of CH to
AML are needed to identify speciﬁc pathways and mole-
cules for development of prognostic tests and therapies to
prevent progression to malignancy. In this study, we have
developed novel inducible mouse models allowing temporal
control of expression of Dnmt3aR878H, a common event in
human CH, and Npm1cA, a common cooperating mutation in
human AML. We ﬁnd that acquisition of Npm1cA/+ mutation
on the background of pre-existing Dnmt3aR878H/+ CH drives
development of MPD, which is transformed to AML upon
subsequent transplantation. Furthermore, increasing the
duration of Dnmt3aR878H/+ CH increased the aggressiveness
of MPD development upon acquisition of Npm1cA/+ muta-
tion and decreased overall survival in mice. Previously, the
combination of Dnmt3aR878H/+ and Npm1cA/+ induced
simultaneously did not cause lethal hematologic malignancy
within a 45-week timeframe [11]. We hypothesize that this is
distinct from our current ﬁndings based on the timeframe of
the observation period of animals and the sequential acqui-
sition of mutations over time with concomitant genetic and
epigenetic evolution. Based on our results, we propose that
accumulation of cellular and molecular alterations over time,
as a consequence of Dnmt3a mutation, synergize with Npm1
mutation to cause more aggressive malignancy. These data
are pertinent for considering the timing and importance of
follow-up mutational screening in individuals with CH.
In our CH model, we ﬁnd that heterozygous Dnmt3aR878H
alone is sufﬁcient to cause expansion of phenotypic and
functional HSCs and MPPs, and confer a competitive
advantage of LTHSCs over wild-type LTHSCs in vivo.
Integrating this phenotype with published models of Dnmt3a
knockout, which demonstrate speciﬁc expansion of LTHSCs
[9], or Dnmt3aR878H mutation, which demonstrate expansion
in both multipotent and myeloid progenitors downstream of
the LTHSC [10, 11], suggest that the Dnmt3aR878H mutation
is distinct from Dnmt3a loss. Dnmt3aR878H can confer
impaired differentiation but not the complete differentiation
block that is observed upon Dnmt3a loss [16], and
Dnmt3aR878H HSCs, unlike Dnmt3a−/− HSCs [9, 16], do not
appear to have overt lineage bias in the context of compe-
titive transplantation.
In experiments examining the hematopoietic stem and
progenitor cell compartment at different stages along the
trajectory of CH to MPD and ﬁnally to AML, we revealed
that Npm1cA/+ drives progressive transition of expansion of
the HSC and MPP compartments in CH to the myeloid-
restricted progenitor cell compartment in AML. Further-
more, these myeloid-restricted progenitor cells represent
LSCs capable of propagating AML in transplanted recipient
mice. Seminal work examining the pre-leukemic state in
AML has suggested that the cell of origin acquiring
DNMT3A mutation is an HSC, which causes an expanded
pool of HSCs and downstream progenitors, within which
additional mutations including NPM1c are acquired to drive
progression to AML [8]. These ﬁndings pointed to GMPs
and/or mixed lineage progenitors (MLP) as the likely
populations in which NPM1c was acquired. This model is
consistent with our ﬁndings that progression of Dnmt3a-
mutant CH to Dnmt3a- and Npm1-mutant AML is accom-
panied by a depletion of the expanded pool of HSCs
observed in CH and a shift towards an expanded pool of
myeloid-restricted progenitors that possess LSC activity.
These data also provide important context for interpretation
of a previously published report demonstrating that
Fig. 4 Dnmt3aR878H/+ Npm1cA/+ MPD progresses to AML following
transplantation. a Experimental design for non-competitive secondary
transplantation of Dnmt3aR878H/+ Npm1cA/+ BM MNCs from primary
recipient mice with MDS/MPD or MPD phenotypes. b Frequency of
donor-derived (CD45.2+) cells in PB of secondary recipient mice at
4 weeks post-transplant and at time of sacriﬁce. Dots represent mean ±
s.e.m. (MPD, n= 7; MDS/MPD, n= 3). Results are from three
independent experiments. c Overall survival of secondary transplant-
recipient mice (MPD, n= 7; MDS/MPD, n= 3). d WBC, RBC, and
PLT counts and e spleen weights of moribund mice (control, n= 4;
+/+ cA/+, n= 10). f Frequency of myeloid, B, and T cells within the
donor-derived CD45.2+ fraction in PB and g Gr-1+ and Gr-1− cells
within donor-derived myeloid PB of moribund mice (control, n= 3;
+/+ cA/+, n= 10). h Representative Giemsa-stained BM cytospins
(far left; 40×, scale bars are 40 μm) and H&E-stained spleen (center;
4×, scale bars are 100 μm) (inset: 40×, scale bars are 40 μm) and liver
sections (far right; 4×, scale bars are 100 μm) from moribund recipient
mice. i Somatic, nonsynonymous mutations in individual genes and
sets of genes, grouped into ﬁve categories. Orange boxes indicate
mutations at VAF 0.10-0.39; green boxes, VAF 0.40–0.59; blue boxes,
VAF 0.60–0.97. In all graphs unless otherwise speciﬁed, dots repre-
sent individual mice, bars indicate mean ± s.e.m. *P < 0.05; **P <
0.01; ***P < 0.001
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conditional knockin of Dnmt3aR878H initiates AML in the
absence of other engineered mutations after a long latency
[10]. This study found that LTHSCs decreased and myeloid
lineage-restricted progenitors were expanded in their
Dnmt3a-mutant AML mice. Based on these data taken
together, we propose that a decline in HSC frequency and
shift toward myeloid-restricted progenitor expansion in the
HSPC compartment may serve as a biomarker for risk or
early progression of CH to AML. Our data suggest that
distinct cooperating mutations, in addition to Npm1, drive
progression of Dnmt3a-mutant CH to MDS/MPD, MPD
and AML. Mutations in the tumor suppressor Cux1 and
RNA splicing factor mutations are associated with MDS/
MPD, while strong selection for mutations activating Ras/
Raf/MAPK signaling are invariably associated with pro-
gression to MPD. Furthermore, transformation to AML is
accompanied by selection for additional mutations in sig-
naling molecules and/or epigenetic regulatory factors.
Fig. 5 Mice with Dnmt3aR878H/+ Npm1cA/+ AML show expansion of
granulocyte-macrophage progenitor cells. a Representative ﬂow cyto-
metric gating for hematopoietic stem and progenitor cells in recipient
mice transplanted with Dnmt3a+/+ Npm1+/+ or Dnmt3aR878H/+
Npm1cA/+ with MDS/MPD, MPD, or AML phenotypes. b Frequency
of LT-HSC, ST-HSC, MPP2, and MPP3 and c GMP, CMP, and MEP in
donor-derived CD45.2+ BM cells (control, n= 2; R878H/+ cA/+MDS/
MPD, n= 2; R878H/+ cA/+ MPD, n= 3; R878H/+cA/+ AML,
n= 4). Results are from two independent experiments
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Mutations in DNMT3A are common in the general
population and increase with aging. With next-generation
sequencing becoming more and more routine as a part of
general medical care, we need better predictive tools to
assess who is at risk for progression from CH to MDS,
MPN or AML in addition to development of new pre-
ventative therapeutic strategies. Addressing a number of
these pressing basic and translational research questions
regarding the evolution of CH to AML will now be possible
by utilizing the in vivo models we have developed. For
example, different stressors and environmental factors (age,
tobacco use, prior radiation therapy) have been hypothe-
sized to facilitate emergence of clinically relevant pheno-
types of the DNMT3A mutation [38]. Our models will not
only permit prospective testing of the effects of stress or
environmental factors on the Dnmt3a-mutant CH pheno-
type, but also whether effects on CH ultimately change the
risk of progression to malignancy upon acquisition of a
cooperating mutation in Npm1. Furthermore, orthogonal
regulation of the Dnmt3a and Npm1 mutations will permit
interrogation of the underlying biological mechanisms by
which these mutations interact to cause malignancy,
including hematopoietic cell-intrinsic interactions (ex.
chromatin regulation, DNA repair) and cell-extrinsic inter-
actions (ex. alterations in the BM cytokine environment).
Lastly, this study serves as a proof-of-principle that utilizing
an inducible, dual-recombinase system is a feasible and
translationally relevant strategy to model combinations of
Fig. 6 Myeloid-restricted progenitor cells are tumor-propagating cells
in Dnmt3aR878H/+ Npm1cA/+ AML. a Experimental design for non-
competitive tertiary transplantation of FACS-sorted Dnmt3aR878H/+
Npm1cA/+ BM myeloid progenitors from secondary recipient mice
with AML. b Overall survival of tertiary transplant recipient mice (n
= 12). Results are from three independent experiments. c WBC, RBC,
and PLT counts in moribund mice (control, n= 3;+/+ cA/+, n= 9).
d Spleen weights of moribund mice (control, n= 3;+/+ cA/+, n=
11). e Representative Giemsa-stained BM cytospin (far left; 40×, scale
bars are 40 μm) and H&E-stained spleen (center; 10×, scale bars are
100 μm) and liver sections (far right; 10×, scale bars are 100 μm) from
moribund recipient mice. In all graphs, dots represent individual mice,
bars indicate mean ± s.e.m. **P < 0.01
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somatic mutations in CH, pre-leukemia and hematologic
malignancy, and to model clonal evolution more broadly in
different malignant contexts.
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